G
Guillermo Garcia-Manero
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1611
Citations - 52621
Guillermo Garcia-Manero is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Myelodysplastic syndromes. The author has an hindex of 108, co-authored 1411 publications receiving 43103 citations. Previous affiliations of Guillermo Garcia-Manero include Sapporo Medical University & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia
Elias Jabbour,Koichi Takahashi,Koichi Takahashi,Xuemei Wang,A. Megan Cornelison,Lynne Abruzzo,Tapan M. Kadia,Gautam Borthakur,Zeev Estrov,Susan O'Brien,Mar Mallo,William G. Wierda,Sherry Pierce,Yue Wei,Francisco Sole,Rui Chen,Hagop M. Kantarjian,Guillermo Garcia-Manero +17 more
TL;DR: It is hypothesized that the dynamic acquisition of cytogenetic abnormalities during the follow up of myelodysplastic syndromes (MDS) could be associated with poor prognosis, and it is shown that ACA occurs in close to one third of patients with IPSS defined lower risk MDS, more common among patients with t‐MDS, but has a significant prognostic impact on de novo MDS.
Journal ArticleDOI
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: Retrospective analysis of survival after long-term follow-up
Monica Cabrero,Elias Jabbour,Farhad Ravandi,Zach Bohannan,Sherry Pierce,Hagop M. Kantarjian,Guillermo Garcia-Manero +6 more
TL;DR: Considering the poor prognosis after HMA failure, HMA interruption should be avoided once a sustained response has been achieved, and patients who received 12 cycles of therapy or more had significantly better OS.
Journal ArticleDOI
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies
Yasmin Abaza,Tapan M. Kadia,Elias J. Jabbour,Marina Konopleva,Gautam Borthakur,Alessandra Ferrajoli,Zeev Estrov,William G. Wierda,Ana Alfonso,Toh Han Chong,Charles Chuah,Liang Piu Koh,B. C. Goh,Julie E. Chang,Daniel E. Durkes,Maria Cielo Foudray,Hagop M. Kantarjian,Xiao Qin Dong,Guillermo Garcia-Manero +18 more
TL;DR: A phase 1 study is conducted to assess the safety, maximum tolerated dose, recommended phase 2 dose, efficacy, pharmacokinetics, and pharmacodynamics of pracinostat in patients with advanced hematological malignancies.
Journal ArticleDOI
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes.
Talha Badar,Keyur P. Patel,Philip A. Thompson,Courtney D. DiNardo,Koichi Takahashi,Monica Cabrero,Gautam Borthakur,Jorge E. Cortes,Marina Konopleva,Tapan M. Kadia,Zach Bohannan,Sherry Pierce,Elias Jabbour,Farhad Ravandi,Naval Daver,Raja Luthra,Hagop M. Kantarjian,Guillermo Garcia-Manero +17 more
TL;DR: It is hypothesized that detection of these mutations at the time of transformation from MDS to AML may lead to poorer outcomes, and FLT3-ITD and RAS mutations had independent prognostic significance for poor outcome.
Journal ArticleDOI
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia.
Francesco Paolo Tambaro,Harjeet Singh,Emily Jones,Michael Rytting,Kris M. Mahadeo,Philip A. Thompson,Naval Daver,Courtney D. DiNardo,Tapan M. Kadia,Guillermo Garcia-Manero,Timothy A. Chan,Shah Rutul R,William G. Wierda +12 more
TL;DR: A single-center, single-arm, Phase I clinical trial is initiated to investigate the feasibility and safety of adoptive transfer of autologous T cells, modified to express a CD33-targeted CAR with 4-1BB and CD3ζ endo-domains and coexpressed with truncated human epidermal growth factor receptor (HER1t) in patients with relapsed/refractory AML.